Baruch Kuppermann, MD
Retina Specialist · Irvine, CANPI 1326128455
Payments from drug & device makers
Across 349 payments — averaging $3980.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$652K
- AbbVie$261K
- Apellis Pharmaceuticals, Inc.$134K
- Novartis$120K
- Eyepoint US, Inc.$46K
- Genentech USA, Inc.$42K
- plus $134K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 51 | $652,304 |
| AbbVie(2 entities) | 138 | $260,616 |
| Apellis Pharmaceuticals, Inc. | 35 | $134,223 |
| Novartis | 14 | $120,243 |
| Eyepoint US, Inc. | 13 | $45,616 |
| Genentech USA, Inc. | 27 | $41,709 |
| Boehringer Ingelheim | 3 | $38,117 |
| Regeneron | 8 | $34,720 |
| Coherus Oncology, Inc. | 8 | $16,058 |
| Regeneron Healthcare Solutions, Inc. | 18 | $14,089 |
| Amgen | 3 | $9,947 |
| Hexal AG | 3 | $7,557 |
| Bausch & Lomb Americas Inc. | 11 | $6,985 |
| F. Hoffmann-la Roche AG | 2 | $4,353 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $403 |
| Nevro Corp. | 2 | $291 |
| Dutch Ophthalmic, USA | 1 | $173 |
| Carl Zeiss Meditec USA, Inc. | 1 | $163 |
| Astellas Pharma US Inc | 2 | $148 |
| Alimera Sciences, Inc. | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $90 |
| Astellas Pharma Global Development | 1 | $61 |
| Rxsight Inc | 1 | $40 |
| Glaukos Corporation | 1 | $18 |
How this compares
$1,389,149 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Irvine
- Mitul MehtaIrvine$192K
- Andrew BrowneIrvine$116K
- Nadeem VaidyaIrvine$18K
- Kapil MishraIrvine$15K
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.